Summary

The current business environment around the biotechnology industry is increasingly challenging for the biotech companies to ensure access to capital, while out-licensing deals with Japanese companies could present an important alternative source of non-dilutive cash. Here, we have summarized the latest trends of the business development in Japan, focusing on the buy-side activities by the Japanese pharmaceutical companies.

Method

……

If you would like to download the full report,  please fill out the form and click “Submit”.